Skip to main content

16-09-2021 | Rheumatology | News | Article

News in brief

Booster dose may enhance COVID-19 vaccination response in people with autoimmune disease

Claire Barnard

medwireNews: Having a booster dose of vaccine against SARS-CoV-2 augments the humoral immune response in the majority of people with immune-mediated inflammatory diseases (IMIDs), suggest findings from a small study.

Among 18 patients who received a single booster dose of a messenger RNA or adenoviral vector vaccine at a median of 77 days after completion of their initial vaccination series, 89% experienced an enhanced antibody response following the booster, say Dorry Segev (Johns Hopkins University, Baltimore, Maryland, USA) and colleagues. The median level of immunoglobulin G antibodies against the SARS-CoV-2 spike protein was 2500 units/mL at a median of 30 days after the booster dose.

The team also found that 80% of the 10 participants who were negative (<0.8 units/mL) for these antibodies after the initial vaccine series were positive following the booster dose, while all six of the people with previous low positive levels (0.8–500 units/mL) had high antibody titers (>2500 units/mL) after the booster. Two people remained negative for anti-spike antibodies following booster vaccination, one of whom was on rituximab therapy and one on mycophenolate.

“Further studies are needed to address safety and efficacy of booster vaccination, as well as optimal adjustment in peri-vaccination timing of immunosuppressive therapies,” conclude Segev and team in a letter to the Annals of the Rheumatic Diseases.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

16 September 2021: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.

Ann Rheum Dis 2021; doi:10.1136/annrheumdis-2021-221206

See the research in context now

with trial summaries, expert opinion and congress coverage